Site icon OncologyTube

Initial Therapy for mRCC: Pro: Immune Checkpoint Inhibitors

Hans Hammers MD, PhD of Johns Hopkins presents “Initial Therapy for mRCC: Pro: Immune Checkpoint Inhibitors” at the 14th International Kidney Cancer Symposium.

Exit mobile version